Jazz Pharmaceuticals plc
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.
6da41569bd
Anne O'Riordan departed as Director at Jazz Pharmaceuticals plc.
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.
MOZAYYX Acquisition appoints Emma Rose Bienvenu as independent director
This filing
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.
Comparable filing
On May 26, 2026, the Board of Directors (the “ Board ”) of MOZAYYX Acquisition Corp. (the “ Company ”) appointed Emma Rose Bienvenu to serve as an independent director of the Company, effective immediately.
Darla Moore resigns from GEE Group board effective June 1, 2026, due to other commitments
This filing
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.
Comparable filing
On June 1, 2026, GEE Group Inc. (the “Company”) (NYSE American: JOB) issued a press release announcing that Ms. Darla Moore, has resigned as a member of the Board of Directors (the “Board”) and from all committees of the Company’s Board effective June 1, 2026, due to the time requirements necessary for her existing and new business commitments.
Sera Prognostics director Jeff Elliott resigns ahead of annual meeting
This filing
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.
Comparable filing
Jeffrey T. Elliott, a member of the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”), notified the Company of his decision to resign from the Board effective as of June 4, 2026
TechnipFMC appoints Eric D. Mullins to Board of Directors effective June 1, 2026
This filing
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.
Comparable filing
the Board elected Eric Mullins to the Board and appointed Mr. Mullins to the Audit Committee of the Board, effective June 1, 2026.
Seres Therapeutics board member Hans-Juergen Woerle resigns, effective May 31, 2026
This filing
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.
Comparable filing
On May 30, 2026, Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a member of the board of directors of Seres Therapeutics, Inc. (the “Company”) and on the committees on which he serves, effective May 31, 2026.
Microchip appoints former SVP Mitch Little to board, effective June 1, 2026
This filing
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.
Comparable filing
appointed Mitch Little, former Senior Vice President, Worldwide Client Engagement of Microchip, as a member of the Board, effective June 1, 2026.
Director Alex Volkov resigns from ProPetro board after Pioneer (Exxon) sells all shares
This filing
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.
Comparable filing
On May 28, 2026, ProPetro Holding Corp. (the “Company”) announced the resignation of Alex V. Volkov from the Company’s Board of Directors (the “Board”).
Deere director Dmitri Stockton will not seek re-election at 2027 annual meeting
This filing
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.
Comparable filing
On May 26, 2026, Dmitri Stockton notified the Board of Directors (the “Board”) of Deere & Company (the “Company”) that he would not stand for re-election as a director at the 2027 annual meeting of stockholders.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.